Physician

Aamir Raza, M.D.

According to 2025 Medicare claims, Aamir Raza, M.D. (NPI: 1578710158) practices nephrology in the Riverside-San Bernardino-Ontario, CA market, with the plurality of this provider's patient population coming from San Bernardino, CA. This provider's primary affiliated billing organization is FACULTY PHYSICIANS AND SURGEONS OF LLUSM (NPI: 1386162949; TIN: 330672915) and primary practice location at 92408-3731.

Raza's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 243 traditional Medicare patients, billed 978 HCPCS/CPT codes, and received $85,863 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,655 prescription claims across 257 beneficiaries totaling $900,666 in drug costs, led by Lokelma (Sodium Zirconium Cyclosilicate). DME data shows 2,800 claims. Open Payments data shows 24 records totaling $765. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $49,086 to $900,666. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,932 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	430	1,033	$92,326
2016	390	843	$75,355
2017	218	547	$43,838
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	190	720	$50,990
2022	213	618	$45,676
2023	240	716	$71,745
2024	243	978	$85,863

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	172	677	$49,086
2016	93	585	$37,662
2017	96	391	$45,008
2018	53	153	$26,811
2019	46	128	$18,837
2020	55	134	$34,709
2021	24	45	$8,956
2022	65	144	$60,111
2023	216	1,199	$1,316,285
2024	257	1,655	$900,666

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	20	$200
2016	N/R	23	$124
2017	N/R	67	$200
2018	N/R	22	$44
2019	N/R	N/R	N/R
2020	N/R	24	$387
2021	N/R	N/R	N/R
2022	N/R	24	$739
2023	332	1,531	$112,540
2024	557	2,800	$222,068

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	74	166	$144
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	49	55	$139
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	155	214	$103
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	77	271	$99
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	146	247	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lokelma	Sodium Zirconium Cyclosilicate	49	1,461	$36,739
Veltassa	Patiromer Calcium Sorbitex	22	810	$22,177
Valganciclovir Hcl	Valganciclovir Hcl	109	3,298	$19,070
Procrit	Epoetin Alfa	16	448	$16,066
Eliquis	Apixaban	25	750	$15,744

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	38	250	$165,086
J7518	Mycophenolic acid, oral, 180 mg	N	56	342	$18,079
J7507	Tacrolimus, immediate release, oral, 1 mg	N	89	457	$13,818
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	143	781	$13,434
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	133	467	$8,388

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$765	Mallinckrodt Hospital Products Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aamir Raza, M.D.?

Tedicare shows public-source Medicare data for Aamir Raza, M.D. (NPI 1578710158), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aamir Raza, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aamir Raza, M.D.?

Aamir Raza, M.D. is linked to FACULTY PHYSICIANS AND SURGEONS OF LLUSM (billing NPI 1386162949) in the available physician profile data.

Does Aamir Raza, M.D. have Open Payments data?

Aamir Raza, M.D. has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.